Market Cap 90.04M P/E - EPS this Y 31.20% Ern Qtrly Grth -
Income -53.75M Forward P/E -2.14 EPS next Y 8.00% 50D Avg Chg -13.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -18.00%
Dividend N/A Price/Book 1.30 EPS next 5Y - 52W High Chg -86.00%
Recommedations 2.80 Quick Ratio 6.92 Shares Outstanding 21.19M 52W Low Chg 10.00%
Insider Own 10.14% ROA -31.10% Shares Float 15.49M Beta -
Inst Own 52.53% ROE -58.90% Shares Shorted/Prior 1.09M/1.46M Price 4.25
Gross Margin - Profit Margin - Avg. Volume 3,416,306 Target Price 7.25
Oper. Margin - Earnings Date Aug 9 Volume 367,715 Change -0.70%
Aprea Therapeutics, Inc. News
07/21/21 Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
06/18/21 Implied Volatility Surging for Aprea (APRE) Stock Options
06/17/21 Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
06/16/21 Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
06/16/21 Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
06/13/21 Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy?
12:47 AM Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth?
05/21/21 Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
05/18/21 Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
05/06/21 Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
04/16/21 Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
04/08/21 Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
03/16/21 Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
02/16/21 Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions?
01/22/21 What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
01/08/21 Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
12/30/20 Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
12/29/20 Don’t Go Bargain Hunting on Aprea Stock, Says Analyst
12/29/20 Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

APRE Chatroom

User Image stocktowatch7 Posted - 5 hours ago

$BNGO, $APRE described at http://www.stocksequity.com/active-stocks/what-do-analysts-recommend-bionano-genomics-inc-nasdaqbngo-aprea-therapeutics-inc-nasdaqapre/

User Image ChasingFreedom Posted - 8 hours ago

$PME Okay so digging into the 1 minute chart on this ticker I noticed there was a 3 candle session where nearly 300k shares were traded that's three quarters of the volume for the whole day in 3 minutes, someone is expecting something pretty big here IMO, now while that is low volume it's 3x the average daily volume and also tells me that once again someone loaded the F***ing boat. China momo is heating up, we have Gap to fill around 1.55 and Technical indicators have lined up on the hourly and 15 minute charts. This is looking better and better the more I dig. In before the crowdπŸ’ͺπŸ’΅πŸ’° $CXDC $LGHL $APRE

User Image ChasingFreedom Posted - 8 hours ago

$APRE The wife is going to love her new Merc convertible when this sleeping giant awakens lol patience will pay huge dividends here IMO πŸ’ͺπŸ’΅πŸ’°

User Image StockAuthority Posted - 9 hours ago

$APRE Gap Goalzzzz 572%

User Image Shan7860 Posted - 10 hours ago

$APRE

User Image St0ckt0k101 Posted - 10 hours ago

$APRE what are yall averages here?? Just wondering...

User Image JFarr4 Posted - 10 hours ago

$APRE just tripled down. Back to waiting!

User Image Bobbyrod Posted - 11 hours ago

$APRE Not selling until we see double digits here! πŸ’ͺπŸ˜ŽπŸ‘

User Image StockAuthority Posted - 11 hours ago

$APRE nhod, wake me 580% higher at the gap fill yaaaawn. Diamond Hands.

User Image rag2riches Posted - 11 hours ago

$APRE I hesitated and missed today's dip.

User Image Gboston10 Posted - 11 hours ago

$APRE πŸšŒπŸšŒπŸšŒπŸšŒπŸš€πŸš€πŸš€πŸš€

User Image Christianmurray Posted - 12 hours ago

$APRE buy em up i know i am bout to put my order in to fulfill my goal!

User Image Bigstakes Posted - 12 hours ago

$APRE Aprea about to be kicking cancers ass!. 53 mutant gene in HALF of all cancers...The next block buster 2022

User Image FloridaKing20 Posted - 13 hours ago

$APRE and $VJET for the 300%+ potential they both possess. @StockAuthority

User Image Fikipe Posted - 13 hours ago

$APRE normal until PR for it to drop

User Image StockAuthority Posted - 13 hours ago

$APRE I dont have a stop, but I do have fresh funds and will buy every dip until 580% gap fill daily. That is all.

User Image radtech00 Posted - 13 hours ago

$APRE

User Image neweros Posted - 14 hours ago

$APRE is there any link where I see the trials which are on fast track with FDA?

User Image Rising_Stocks_LT Posted - 15 hours ago

$APRE wanted to reemphasize, how much this company has going on in 2nd half of 2021, which we are already in month 2 of 6. Meetings with FDA for both trial outcomes, which they have Fast track and orphan drug status for.

User Image Rising_Stocks_LT Posted - 15 hours ago

$APRE β€œThe post-transplant RFS and OS data with eprenetapopt and azacitidine maintenance therapy in these very difficult-to-treat TP53 mutant MDS and AML patients are incredibly exciting,” said trial principal investigator Asmita Mishra, M.D., of the H. Lee Moffitt Cancer Center and Research Institute. β€œAlthough transplant is currently the only potentially curative treatment for patients with TP53 mutant MDS and AML, the risk of relapse with current standard of care remains unacceptably high and the median OS post-transplant is very limited at 8 months or less. Post-transplant maintenance therapy with eprenetapopt and azacitidine could, if approved, represent a new treatment paradigm that meaningfully improves outcomes for these patients with limited treatment options.”

User Image Rising_Stocks_LT Posted - 15 hours ago

$APRE BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. The Company plans to discuss the data from this Phase 2 clinical trial with the U.S. Food and Drug Agency (FDA) in the second half of 2021 and expects to present data at a future scientific or medical conference.

User Image Rising_Stocks_LT Posted - 15 hours ago

$APRE β€œWe are pleased with these results from the combination of eprenetapopt with venetoclax and azacitidine in this very difficult-to-treat TP53 mutant AML population, a patient group with significant unmet medical need,” said Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics. β€œThese data, which follow the recent granting of Fast Track and Orphan Drug designations by FDA, provide further demonstration of the potential for eprenetapopt in the treatment of myeloid malignancies. We continue to make excellent progress across our myeloid malignancies program and look forward to providing an update in July 2021 on our Phase 2 trial evaluating eprenetapopt with azacitidine as maintenance therapy in TP53 mutant MDS and AML patients who have received allogeneic stem cell transplant.”

User Image Rising_Stocks_LT Posted - 15 hours ago

$APRE BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Phase 1/2 trial evaluating the frontline treatment of eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML has met the pre-specified primary efficacy endpoint of complete remission (CR) rate. The Company plans to discuss the dataset with the U.S. Food and Drug Agency (FDA) in the second half of 2021 and expects to present data from the trial at a future scientific or medical conference.

User Image Bigstakes Posted - 16 hours ago

$APRE If Aprea s drug gets approved first in class.LOCK BUSTER potential..Just have to ride this out..We are in great shape, low float plenty of cash, amazing management .Insiders own a nice chunk of the stock.Their interest aligns with ours....

User Image StockAuthority Posted - 17 hours ago

$APRE down 1% on 62k volume, one of these days its gonna be up 580% on like 62 MILLION volume, mark this post ;-)

User Image unsunghero Posted - 17 hours ago

$APRE Same shit everyday with this garbage stock.

User Image StockAuthority Posted - 17 hours ago

$APRE added more, 580% more gain to go!

User Image Rocshan Posted - 17 hours ago

$APRE 578.5% more to go.

User Image Xtrader007 Posted - 1 day ago

@michaelbozzello please have ticker $APRE fixed. No chart + no price Thank you.

User Image Christianmurray Posted - 1 day ago

$APRE Listen to all the doctors stating apr-246 is very promising or some random person that has puts or shorting the ticker on a board hmmmmm....

Analyst Ratings
RBC Capital Sector Perform Mar 17, 21
RBC Capital Sector Perform Dec 29, 20
Morgan Stanley Equal-Weight Dec 16, 20
Berenberg Buy Dec 16, 20
HC Wainwright & Co. Neutral Nov 25, 20
Baird Outperform Nov 25, 20
Morgan Stanley Equal-Weight Nov 25, 20
Morgan Stanley Equal-Weight Nov 25, 20
RBC Capital Outperform Nov 25, 20